Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

14 Apr 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · NSCLC (Non-small Cell Lung Cancer) · Phase 2 · Enrollment 20 · Sponsor: Tianjin Medical University Cancer Institute and Hospital

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 14 Apr 2026. The item focuses on Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure. Open the detail page to review the full original feed content.